Ms. Katrina McClatchey

Thursday, 04 November 2004 18:00 Katrina McClatchey
...
Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law and an associate at the Oklahoma City law firm of Dunlap, Codding & Rogers, P.C. Below, Ms. McClatchey discusses the function and jurisdiction of the European Patent Convention (EPC) treaty and the European Patent Office (EPO) that the treaty established. The EPO issues a single patent that is enforceable in as many countries as the applicant wishes to designate. This makes obtaining patent protection in many European countries not only possible but extremely efficient as well. While the requirements for a European patent are similar to the requirements for a United States patent, Ms. McClatchey highlights some important distinctions of which biotechnologists should be aware.
...
Monday, 04 October 2004 18:00 Katrina McClatchey
...
Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law. She wrote this eBrief under the direction of Professor Drew Kershen while she was participating in the Project on Intellectual Property Rights in Living Matter. Below, Ms. McClatchey discusses the impact of a decision in the year 2000 in the case of NOVARTIS/Transgenic Plant upon European Patent Convention (EPC) jurisprudence. Ms. McClatchey concludes that although the EPC may exclude a plant-related invention if the subject-matter claimed is a product which is strictly limited to a specific plant variety or specific plant varieties, the European patent nevertheless remains a viable option for biotechnologists with plant-related inventions.

By: Katrina McClatchey - html | pdf* - (2004 - 2005 BOE)
...
Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law and an associate at the Oklahoma City law firm of Dunlap, Codding & Rogers, P.C. Below, Ms. McClatchey discusses the function and reach of the European Patent Convention (EPC) treaty and the European Patent Office (EPO) that the treaty established. The EPO issues a single patent that is enforceable in as many countries as the applicant wishes to designate. This makes obtaining patent protection in many European countries not only possible but extremely efficient as well. While the requirements for a European patent are similar to the requirements for a United States patent, Ms. McClatchey highlights some important distinctions of which biotechnologists should be aware.

European Union Archives

2 OKLA. J.L. & TECH. 22 (2004)

THE EFFECT OF THE "ONCO-MOUSE" DECISIONS ON THE EXCEPTION TO PATENTABILITY FOR "ANIMAL VARIETIES" UNDER THE EUROPEAN PATENT CONVENTION By: Katrina McClatchey - html | pdf* - (2004 - 2005 BOE)
...
By: Katrina McClatchey - html | pdf* - (2004 - 2005 BOE)

Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law. Ms. McClatchey wrote this eBrief under the direction of Professor Drew Kershen while working on the Project on Intellectual Property Rights in Living Matter.
...
Below, Ms. McClatchey discusses recent and significant decisions in the European Patent Office (EPO) regarding an animal-related invention known as the "Onco-mouse" and provides guidance on how the exception to patentability for "animal varieties" under European Patent Convention (EPC) Article 53(b) has been interpreted and implemented with respect to animal-related inventions.
...
© 2004 Katrina McClatchey

Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law and an associate at the Oklahoma City law firm of Dunlap, Codding & Rogers, P.C. Below, Ms. McClatchey discusses the function and jurisdiction of the European Patent Convention (EPC) treaty and the European Patent Office (EPO) that the treaty established. The EPO issues a single patent that is enforceable in as many countries as the applicant wishes to designate. This makes obtaining patent protection in many European countries not only possible but extremely efficient as well. While the requirements for a European patent are similar to the requirements for a United States patent, Ms. McClatchey highlights some important distinctions of which biotechnologists should be aware.
...
© 2004 Katrina McClatchey
...
65 For a more comprehensive discussion on the application of the "plant varieties" exception, see Katrina McClatchey, The Effect of the "Onco-Mouse" Decisions on the Exception to Patentability for "Animal Varieties" Under the European Patent Convention, 2 Okla. J.L. & Tech. 22 (2004). [back]
...
68 For a more comprehensive discussion on the application of the "animal varieties" exception, see Katrina McClatchey, The Impact of Novartis on the European Patent Convention's Exception to Patentability for "Plant Varieties," 2 Okla. J.L. & Tech. 21 (2004). [back]

Katrina McClatchey is a 2004 graduate of the University of Oklahoma College of Law. She wrote this eBrief under the direction of Professor Drew Kershen while she was participating in the Project on Intellectual Property Rights in Living Matter. Below, Ms. McClatchey discusses the impact of a decision in the year 2000 in the case of NOVARTIS/Transgenic Plant upon European Patent Convention (EPC) jurisprudence. Ms. McClatchey concludes that although the EPC may exclude a plant-related invention if the subject-matter claimed is a product which is strictly limited to a specific plant variety or specific plant varieties, the European patent nevertheless remains a viable option for biotechnologists with plant-related inventions.
...
© 2004 Katrina McClatchey